Adcendo

Last updated: November 25, 2024

The team
The team
Denmark | Funding: $249.6M (+)

Website: https://adcendo.dk/

ADCendo is dedicated to developing antibody-drug conjugates (ADCs) for treatment of cancer. We are taking the ADC approach to new levels through a focus on cancer-associated targets that are professional internalizers and allow for superior selectivity via highly preferential cancer expression.